David J Roh1, David J Albers2, Jessica Magid-Bernstein2, Kevin Doyle2, Eldad Hod2, Andrew Eisenberger2, Santosh Murthy2, Jens Witsch2, Soojin Park2, Sachin Agarwal2, E Sander Connolly2, Mitchell S V Elkind2, Jan Claassen2. 1. From Vagelos College of Physicians and Surgeons (D.J.R., D.J.A., J.M.-B., K.D., E.H., A.E., S.P., S.A., E.S.C., M.S.V.E., J.C.), Columbia University; Weill Cornell Medical Center (S.M.), New York, NY; and Yale School of Medicine (J.W.), New Haven, CT. dr2753@cumc.columbia.edu. 2. From Vagelos College of Physicians and Surgeons (D.J.R., D.J.A., J.M.-B., K.D., E.H., A.E., S.P., S.A., E.S.C., M.S.V.E., J.C.), Columbia University; Weill Cornell Medical Center (S.M.), New York, NY; and Yale School of Medicine (J.W.), New Haven, CT.
Abstract
OBJECTIVE: Studies have independently shown associations of lower hemoglobin levels with larger admission intracerebral hemorrhage (ICH) volumes and worse outcomes. We investigated whether lower admission hemoglobin levels are associated with more hematoma expansion (HE) after ICH and whether this mediates lower hemoglobin levels' association with worse outcomes. METHODS: Consecutive patients enrolled between 2009 and 2016 to a single-center prospective ICH cohort study with admission hemoglobin and neuroimaging data to calculate HE (>33% or >6 mL) were evaluated. The association of admission hemoglobin levels with HE and poor clinical outcomes using modified Rankin Scale (mRS 4-6) were assessed using separate multivariable logistic regression models. Mediation analysis investigated causal associations among hemoglobin, HE, and outcome. RESULTS: Of 256 patients with ICH meeting inclusion criteria, 63 (25%) had HE. Lower hemoglobin levels were associated with increased odds of HE (odds ratio [OR] 0.80 per 1.0 g/dL change of hemoglobin; 95% confidence interval [CI] 0.67-0.97) after adjusting for previously identified covariates of HE (admission hematoma volume, antithrombotic medication use, symptom onset to admission CT time) and hemoglobin (age, sex). Lower hemoglobin was also associated with worse 3-month outcomes (OR 0.76 per 1.0 g/dL change of hemoglobin; 95% CI 0.62-0.94) after adjusting for ICH score. Mediation analysis revealed that associations of lower hemoglobin with poor outcomes were mediated by HE (p = 0.01). CONCLUSIONS: Further work is required to replicate the associations of lower admission hemoglobin levels with increased odds of HE mediating worse outcomes after ICH. If confirmed, an investigation into whether hemoglobin levels can be a modifiable target of treatment to improve ICH outcomes may be warranted.
OBJECTIVE: Studies have independently shown associations of lower hemoglobin levels with larger admission intracerebral hemorrhage (ICH) volumes and worse outcomes. We investigated whether lower admission hemoglobin levels are associated with more hematoma expansion (HE) after ICH and whether this mediates lower hemoglobin levels' association with worse outcomes. METHODS: Consecutive patients enrolled between 2009 and 2016 to a single-center prospective ICH cohort study with admission hemoglobin and neuroimaging data to calculate HE (>33% or >6 mL) were evaluated. The association of admission hemoglobin levels with HE and poor clinical outcomes using modified Rankin Scale (mRS 4-6) were assessed using separate multivariable logistic regression models. Mediation analysis investigated causal associations among hemoglobin, HE, and outcome. RESULTS: Of 256 patients with ICH meeting inclusion criteria, 63 (25%) had HE. Lower hemoglobin levels were associated with increased odds of HE (odds ratio [OR] 0.80 per 1.0 g/dL change of hemoglobin; 95% confidence interval [CI] 0.67-0.97) after adjusting for previously identified covariates of HE (admission hematoma volume, antithrombotic medication use, symptom onset to admission CT time) and hemoglobin (age, sex). Lower hemoglobin was also associated with worse 3-month outcomes (OR 0.76 per 1.0 g/dL change of hemoglobin; 95% CI 0.62-0.94) after adjusting for ICH score. Mediation analysis revealed that associations of lower hemoglobin with poor outcomes were mediated by HE (p = 0.01). CONCLUSIONS: Further work is required to replicate the associations of lower admission hemoglobin levels with increased odds of HE mediating worse outcomes after ICH. If confirmed, an investigation into whether hemoglobin levels can be a modifiable target of treatment to improve ICH outcomes may be warranted.
Authors: S M Davis; J Broderick; M Hennerici; N C Brun; M N Diringer; S A Mayer; K Begtrup; T Steiner Journal: Neurology Date: 2006-04-25 Impact factor: 9.910
Authors: Douglas B Cines; Tatiana Lebedeva; Chandrasekaran Nagaswami; Vincent Hayes; Walter Massefski; Rustem I Litvinov; Lubica Rauova; Thomas J Lowery; John W Weisel Journal: Blood Date: 2013-12-13 Impact factor: 22.113
Authors: C David Mazer; Richard P Whitlock; Dean A Fergusson; Judith Hall; Emilie Belley-Cote; Katherine Connolly; Boris Khanykin; Alexander J Gregory; Étienne de Médicis; Shay McGuinness; Alistair Royse; François M Carrier; Paul J Young; Juan C Villar; Hilary P Grocott; Manfred D Seeberger; Stephen Fremes; François Lellouche; Summer Syed; Kelly Byrne; Sean M Bagshaw; Nian C Hwang; Chirag Mehta; Thomas W Painter; Colin Royse; Subodh Verma; Gregory M T Hare; Ashley Cohen; Kevin E Thorpe; Peter Jüni; Nadine Shehata Journal: N Engl J Med Date: 2017-11-12 Impact factor: 91.245
Authors: J Claude Hemphill; Steven M Greenberg; Craig S Anderson; Kyra Becker; Bernard R Bendok; Mary Cushman; Gordon L Fung; Joshua N Goldstein; R Loch Macdonald; Pamela H Mitchell; Phillip A Scott; Magdy H Selim; Daniel Woo Journal: Stroke Date: 2015-05-28 Impact factor: 7.914
Authors: H Bart Brouwers; Yuchiao Chang; Guido J Falcone; Xuemei Cai; Alison M Ayres; Thomas W K Battey; Anastasia Vashkevich; Kristen A McNamara; Valerie Valant; Kristin Schwab; Susannah C Orzell; Linda M Bresette; Steven K Feske; Natalia S Rost; Javier M Romero; Anand Viswanathan; Sherry H-Y Chou; Steven M Greenberg; Jonathan Rosand; Joshua N Goldstein Journal: JAMA Neurol Date: 2014-02 Impact factor: 18.302
Authors: David O Okonkwo; Lori A Shutter; Carol Moore; Nancy R Temkin; Ava M Puccio; Christopher J Madden; Norberto Andaluz; Randall M Chesnut; M Ross Bullock; Gerald A Grant; John McGregor; Michael Weaver; Jack Jallo; Peter D LeRoux; Dick Moberg; Jason Barber; Christos Lazaridis; Ramon R Diaz-Arrastia Journal: Crit Care Med Date: 2017-11 Impact factor: 7.598
Authors: Julián N Acosta; Audrey C Leasure; Lindsey R Kuohn; Cameron P Both; Nils H Petersen; Lauren H Sansing; Charles C Matouk; Fernando Testai; Carl D Langefeld; Daniel Woo; Hooman Kamel; Santosh B Murthy; Adnan Qureshi; Stephan A Mayer; Kevin N Sheth; Guido J Falcone Journal: Crit Care Med Date: 2021-05-01 Impact factor: 7.598
Authors: Jens Witsch; Bob Siegerink; Christian H Nolte; Maximilian Sprügel; Thorsten Steiner; Matthias Endres; Hagen B Huttner Journal: Neurol Res Pract Date: 2021-05-03